<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903288</url>
  </required_header>
  <id_info>
    <org_study_id>PTC-AADC-GT-002</org_study_id>
    <nct_id>NCT04903288</nct_id>
  </id_info>
  <brief_title>A Study of SmartFlow® Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants</brief_title>
  <official_title>An Open-Label Trial to Address the Safety of the SmartFlow® MR Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will have a trial phase and an extension phase. The primary objective of the trial&#xD;
      phase is to assess the safety of the SmartFlow® MR Compatible Ventricular Cannula for&#xD;
      administering eladocagene exuparvovec to pediatric participants with aromatic L-amino acid&#xD;
      decarboxylase (AADC) deficiency. The extension phase is designed to capture additional&#xD;
      clinical information for eladocagene exuparvovec, including changes in motor development,&#xD;
      AADC-specific symptoms, and other pharmacodynamic (PD) measures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR Compatible Ventricular Cannula</measure>
    <time_frame>Baseline (Day 1) up to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Positron Emission Tomography (PET) Imaging of Putaminal-Specific L-6-[18F] Fluoro-3,4-Dihydroxyphenylalnine (18F-DOPA) PET Uptake at the End of the Trial Phase (Week 8)</measure>
    <time_frame>Baseline (Day 1), Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>AADC Deficiency</condition>
  <arm_group>
    <arm_group_label>Eladocagene Exuparvovec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive eladocagene exuparvovec intraoperatively at 1.8×10^11 vector genomes (vg) via SmartFlow® MR Compatible Ventricular Cannula in a single operative session. Participants will receive standard of care for their AADC deficiency during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Eladocagene Exuparvovec</intervention_name>
    <description>Four 0.08 milliliters (mL) infusions at a dose of 0.45×10^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10^11 vg and a total volume of 320 μl per participant.</description>
    <arm_group_label>Eladocagene Exuparvovec</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric participants must have genetically-confirmed AADC deficiency with typical&#xD;
             clinical characteristics and decreased AADC enzyme activity in plasma.&#xD;
&#xD;
          -  Cranium sufficiently developed to allow placement of ClearPoint® system for&#xD;
             stereotactic surgery.&#xD;
&#xD;
          -  Persistent neurological defects secondary to AADC deficiency despite standard medical&#xD;
             therapy (dopamine agonists, monoamine oxidase inhibitor, pyridoxine, or other forms of&#xD;
             vitamin B6) in the opinion of the investigator.&#xD;
&#xD;
          -  Unable to ambulate independently (with or without assistive device).&#xD;
&#xD;
          -  Baseline hematology, chemistry, and coagulation values within the normal pediatric&#xD;
             laboratory value ranges, unless in the investigator's opinion the out of range values&#xD;
             are not clinically significant with respect to the participant's suitability for&#xD;
             surgery.&#xD;
&#xD;
          -  Participant must test negative for coronavirus disease of 2019 (COVID-19) a maximum of&#xD;
             72 hours prior to receiving gene therapy.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test at screening and&#xD;
             baseline and agree to abstinence or double-barrier form of contraception for the&#xD;
             duration of the study following discharge from the hospital (acceptable methods will&#xD;
             be determined by the site).&#xD;
&#xD;
          -  Males sexually active with females of childbearing potential must agree to use a&#xD;
             barrier method of birth control during the study following discharge from the&#xD;
             hospital.&#xD;
&#xD;
          -  Parent(s)/legal guardian(s) of the participant must agree to comply with the&#xD;
             requirements of the study, including the need for frequent and prolonged follow up.&#xD;
&#xD;
          -  Parent(s)/legal guardian(s) with custody of the participant must give their consent&#xD;
             for the participant to enroll in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant has presence of other significant medical or neurological conditions&#xD;
             that would create an unacceptable operative or anesthetic risk.&#xD;
&#xD;
          -  Participants with pyridoxine 5'-phosphate oxidase or tetrahydrobiopterin (BH4)&#xD;
             deficiency.&#xD;
&#xD;
          -  Contraindication for imaging studies (computed tomography [CT] scan, PET, or magnetic&#xD;
             resonance imaging [MRI]), including sedation limitations or metal that would interfere&#xD;
             with a brain MRI.&#xD;
&#xD;
          -  Anti-adeno-associated virus, serotype 2 (anti-AAV2) antibody titer higher than 1:1200&#xD;
             or &gt;1 optical density value by enzyme-linked immunosorbent assay.&#xD;
&#xD;
          -  Participants who have received treatment with other experimental therapies within the&#xD;
             last 24 weeks prior to planned gene therapy administration, or any treatment ever with&#xD;
             a gene therapy.&#xD;
&#xD;
          -  Evidence of a clinically active infection.&#xD;
&#xD;
          -  Females who are pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-866-562-4620</phone>
    <email>medinfo@ptcbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Sklar</last_name>
      <email>msklar7@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anthony Bet</last_name>
      <email>abet0915@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Grant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Porter</last_name>
      <email>adam.porter@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Scellig Stone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Pamanes</last_name>
      <email>Claudia.pamanes@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Vestal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Wisor</last_name>
      <email>sxwisor@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Daniel J. Curry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

